Belviq
Eisai withdraws weight loss drug Belviq after FDA highlights cancer risk
February 14, 2020Medical Communications, Research and Development, Sales and Marketing Belviq, Eisai, FDA, pharma
The FDA has requested that Eisai withdraw its weight loss drug Belviq (lorcaserin) and Belviq XR from the US market …
FDA panel backs liraglutide for obesity
September 12, 2014Manufacturing and Production, Sales and Marketing Arena Pharmaceuticals, Belviq, Novo Nordisk, Qsymia, Victoza, Vivus, diabetes, obesity
An FDA panel has voted 14-1 to allow a form of Novo Nordisk’s type 2 diabetes treatment Victoza to help …
Doctor questions FDA’s diet drug approvals
August 23, 2013Research and Development, Sales and Marketing BMJ, Belviq, EMA, FDA, Vivus, diet pills, obesity
FDA clears Arena and Eisai’s obesity drug
June 28, 2012Sales and Marketing Arena, Belviq, Eisai, FDA, Qnexa, Roche, obesity
Eisai and Arena’s Belviq has gained FDA approval, making it the first obesity drug to be approved in over ten …
Latest content
Boyds expands Regulatory Affairs team to support growing demand
October 16, 2026
Sterling doubles ADC manufacturing capacity at Welsh facility
October 16, 2026
Femtosecond laser cuts lung tumour margin assessment time
October 15, 2026
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
October 15, 2026
